Article
Cardiac & Cardiovascular Systems
Naseeb K. Malhi, Claire L. Allen, Elizabeth Stewart, Katherine L. Horton, Federica Riu, Jennifer Batson, Winfried Amoaku, Jonathan C. Morris, Kenton P. Arkill, David O. Bates
Summary: This study demonstrates that SRPK1 is activated in diabetes, and its inhibition can switch VEGF splicing, reducing retinal permeability and edema in diabetic retinopathy.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
(2022)
Article
Cell Biology
Rui Niu, Ze-Tong Nie, Lin Liu, Yu-Wen Chang, Jian-Qun Shen, Qiong Chen, Li-Jie Dong, Bo-Jie Hu
Summary: The study showed that in PDR patients, anti-VEGF treatment led to increased retinal fibrosis, while a dual-target treatment reduced fibrosis, indicating that FSTL1 may be involved in the pathogenesis of PDR and is associated with fibrosis caused by anti-VEGF treatment.
Article
Plant Sciences
Xuan-xuan Zhang, Ya-li Ji, Li-ping Zhu, Zi-han Wang, Chang-qian Fang, Cui-hua Jiang, Ke Pan, Jian Zhang, Zhi-qi Yin
Summary: The study aimed to investigate whether AA alleviates DR by activating the AMPK/mTOR/HO-1 regulated autophagy pathway. Results showed that AA could prevent retinal damage and cell apoptosis through the AMPK-mTOR-regulated autophagy pathway.
JOURNAL OF ETHNOPHARMACOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Jing Feng, Weiqiang Yang, Fuxiao Luan, Fang Ma, Yingjie Wang, Yiquan Zhang, Xuhui Liu, Li Chen, Xiaofeng Hu, Yong Tao
Summary: Diabetic retinopathy is a common and serious complication of diabetes, and there is currently no effective treatment for early stage. However, apelin has been found to potentially reduce vascular leakage by protecting pericytes, which suggests a promising new direction for early treatment.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Biochemistry & Molecular Biology
Bente Juhl, Flemming Klein, Toke Bek, Line Petersen
Summary: Pregnancy is a risk factor for the development or aggravation of diabetic retinopathy. There may be a relationship between low plasma vitamin C (vitC) levels during pregnancy and the progression of diabetic retinopathy in women with type 1 diabetes.
Article
Pharmacology & Pharmacy
Amit Joharapurkar, Vishal Patel, Samadhan Kshirsagar, Maulik S. Patel, Hardikkumar Savsani, Mukul Jain
Summary: Saroglitazar showed significant benefits in reducing retinal vascular damage in diabetic rats, as well as in decreasing neovascularization in oxygen-induced retinopathy and VEGF-induced angiogenesis.
EUROPEAN JOURNAL OF PHARMACOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Liyang Ji, Hong Tian, Keith A. Webster, Wei Li
Summary: Diabetic retinopathy is the leading cause of vision loss in working adults in developed countries, now recognized as a neurovascular disorder. Disturbance of the neurovascular unit can lead to vision-threatening clinical manifestations. While VEGF inhibitors are widely used to treat DR, their limited efficacy suggests the involvement of other signaling molecules in the pathogenesis of the disease.
CELLULAR AND MOLECULAR LIFE SCIENCES
(2021)
Article
Medicine, Research & Experimental
Mohammed Nadim Sardoiwala, Shakti Nagpal, Babita Bhatt, Subhasree Roy Choudhury, Surajit Karmakar
Summary: Oxidative stress, reactive oxygen species generation, and overexpression of VEGF are characteristic events in diabetic retinopathy. The downregulation of VEGF and anti-inflammatory action are important for DR therapy. In this study, melatonin-loaded polydopamine nanoparticles were synthesized using a reverse microemulsion method to improve melatonin delivery and replenish VEGF downregulation.
MOLECULAR PHARMACEUTICS
(2023)
Review
Integrative & Complementary Medicine
Fatemeh Sanie-Jahromi, Zahra Zia, Mehrdad Afarid
Summary: This study reviews the effects of garlic on diabetes, VEGF, and BDNF, as well as its impact on diabetic retinopathy. The findings indicate that garlic has beneficial effects in treating diabetes, inhibiting angiogenesis, and protecting against neurodegeneration. Garlic can be considered as a complementary treatment option for diabetic retinopathy, supported by available clinical evidence.
Article
Pharmacology & Pharmacy
Claudio Bucolo, Annalisa Barbieri, Ilaria Vigano, Nicoletta Marchesi, Francesco Bandello, Filippo Drago, Stefano Govoni, Gianpaolo Zerbini, Alessia Pascale
Summary: The study found that the retina of diabetic mice exhibits changes similar to patients with diabetic retinopathy in terms of neurodegeneration and pro-angiogenic shift. The time-dependent increase in VEGF-A(164) protein expression suggests that pharmacological intervention in diabetic retinopathy should be chosen based on the specific stages of the pathology.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Medicine, General & Internal
Alessandro Arrigo, Emanuela Aragona, Francesco Bandello
Summary: Diabetic retinopathy is a common complication of diabetes that can cause visual impairment. Anti-VEGF therapies have significantly improved the management of proliferative diabetic retinopathy. The role of anti-VEGF as a substitute for laser treatment or as a combination therapy is still debated. Overall, anti-VEGF treatments are considered the first-line choice for diabetic retinopathy management.
ANNALS OF MEDICINE
(2022)
Article
Biochemistry & Molecular Biology
Sara Rezzola, Jessica Guerra, Adwaid Manu Krishna Chandran, Alessandra Loda, Anna Cancarini, Piergiuseppe Sacristani, Francesco Semeraro, Marco Presta
Summary: Proliferative diabetic retinopathy (PDR) is a major complication of diabetes mellitus, resulting from inflammation among endothelial cells, neurons, and glia. While anti-vascular endothelial growth factor (VEGF) interventions are the current therapeutic option for PDR, their impact on Muller cell activation remains unclear. Additional modulators besides VEGF have been found to play a role in Muller cell activation, suggesting potential for novel therapeutic strategies in PDR.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Multidisciplinary Sciences
Yaowu Qin, Jing Zhang, Savalan Babapoor-Farrokhran, Brooks Applewhite, Monika Deshpande, Haley Megarity, Miguel Flores-Bellver, Silvia Aparicio-Domingo, Tao Ma, Yuan Rui, Stephany Y. Tzeng, Jordan J. Green, M. Valeria Canto-Soler, Silvia Montaner, Akrit Sodhi
Summary: For patients with proliferative diabetic retinopathy (PDR) who do not respond adequately to pan-retinal laser photocoagulation (PRP) or anti-vascular endothelial growth factor (VEGF) therapies, targeting the HIF-2 alpha/PAI-1 axis may be an effective adjunct therapy for the treatment of PDR patients.
Article
Medicine, General & Internal
Chunmiao Wang, Ruijin Ran, Xin Jin, Xiaohong Zhu
Summary: This study found that elevated concentrations of selenium in plasma and vitreous may be an important risk factor for diabetic retinopathy in patients with type 2 diabetes. Additionally, increased VEGF levels in the eyes may be closely related to intraocular selenium concentrations in patients with proliferative diabetic retinopathy.
Review
Immunology
Ankita Sood, Suman Baishnab, Isha Gautam, Priya Choudhary, Damanpreet Kaur Lang, Ravinder Singh Jaura, Thakur Gurjeet Singh
Summary: Diabetic retinopathy is a common complication of diabetes mellitus that leads to visual impairment and blindness. Its etiology is unclear and current treatment strategies are limited in efficacy. Early diagnosis using a sensitive and specific biomarker is crucial for better therapeutic strategies. Current therapeutic options have adverse effects and are economically constrained. Surgical interventions are used when other treatments fail. This review highlights diagnostic tools, emerging biomarkers, pathological mechanisms, and future treatment options for diabetic retinopathy.
INFLAMMOPHARMACOLOGY
(2023)